TRex Bio Files For IPO As Collaboration With Eli Lilly Deepens (Pending:TRXB)
Why now
Thesis: TRex Bio IPO highlights Lilly partnership
Catalyst to watch: IPO pricing and trial data
Main risk: Early-stage clinical failure risk
Why it matters
Biotech IPO filing with deepening Lilly collaboration; sector-relevant but early-stage.
Sources
- googlenews · news.google.com · 2026-09-24 18:58 UTC